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Conclusion: Clearly, the survival gains associated with the foregoing drugs are only 
modest. Despite this, there would be a large negative impact associated with approval 
delays even if factors such as co-morbidities, performance status, ability to pay, etc, limit 
the number of patients treated to a fraction of the total dying from a specific malignancy. 
There are numerous opportunities to improve efficiency of cancer drug approval without 
sacrificing safety or data integrity. This requires urgent attention. 
Keywords: regulatory delays, Life-years lost, urgent need for reform
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ORAL29.01 Results From Phase III Trials of Anamorelin in Advanced Non-Small 
Cell Lung Cancer Patients with Cachexia: ROMANA 1 and 2 Amy Abernethy1, 
Kenneth Fearon2, John Friend3, Ying Yan3, Elizabeth Duus3, David Currow4 1Durham 
University, Durham/NC/United States of America, 2Western General Hospital, Edinburgh/
United Kingdom, 3Helsinn Therapeutics (Us), Inc., Iselin/NJ/United States of America, 
4Flinders University, Adelaide/SA/Australia
Background: Cachexia is a debilitating condition often observed in patients with 
advanced non-small cell lung cancer (NSCLC). A decrease in body weight (BW), in 
particular loss of lean body mass (LBM), is a primary characteristic, and is associated 
with worsening functional status, quality of life, and survival. Despite the high prevalence 
and substantial clinical impact of cachexia in patients with advanced cancer, limited 
therapeutic options exist. Anamorelin is a novel, orally active, selective ghrelin receptor 
agonist that mimics the appetite-enhancing and anabolic effects of ghrelin. ROMANA 
1 and 2 are two randomized, double-blind, Phase III trials evaluating the efficacy and 
safety of anamorelin in patients with advanced NSCLC and cachexia. Methods: In 
ROMANA 1 (NCT01387269; N=484) and ROMANA 2 (NCT01387282; N=495), patients 
with unresectable stage III/IV NSCLC and cachexia (≥5% weight loss during prior 6 
months or body mass index <20kg/m2) were randomized (2:1) to anamorelin 100 mg 
daily or placebo, for 12 weeks. Co-primary endpoints were change in LBM and handgrip 
strength (HGS) over 12 weeks. Secondary endpoints included change in BW and in the 
anorexia/cachexia domain of the Functional Assessment of Anorexia/Cachexia Therapy 
questionnaire over 12 weeks, and pooled 1-year overall survival (OS) from both studies. 
Exploratory endpoints included summarizing the incidence of patients who maintained/
gained LBM from baseline during 12 weeks by treatment group. Post-hoc analysis 
compared OS data in patients who had decrease in LBM during 12 weeks versus those 
who maintained/gained LBM. Safety and tolerability of anamorelin were also evaluated. 
Results: Over 12 weeks, anamorelin significantly increased median LBM versus placebo 
in ROMANA 1 (1.10 vs –0.44 kg; p<0.001) and ROMANA 2 (0.75 vs –0.96 kg; p<0.001); 
in both studies there was no difference in HGS changes between treatment arms. A 
significantly greater proportion of patients in the anamorelin arm versus the placebo arm 
maintained/gained LBM in both ROMANA 1 (58.1% vs 36.9%; p<0.001) and ROMANA 
2 (51.5% vs 26.5%; p<0.001). Post-hoc analysis showed that OS was improved for 
patients who maintained/gained LBM versus patients who lost LBM (HR, 0.53 [95% CI, 
0.42, 0.68]; p<0.001). Anamorelin-treated patients also significantly gained BW (2.20 
vs 0.14 kg; p<0.001, and 0.95 vs –0.57 kg; p<0.001), and had significantly improved 
anorexia-cachexia symptoms and concerns (4.12 vs 1.92; <0.001, and 3.48 vs 1.34; 
p=0.002), compared with placebo-treated patients, in ROMANA 1 and 2, respectively. 
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ORAL11.01 Bevacizumab 15mg/kg Plus Cisplatin-Pemetrexed (CP) vs CP in 
Malignant Pleural Mesothelioma (MPM): IFCT-GFPC-0701 MAPS Randomized 
Phase 3 Trial Arnaud Scherpereel1, Julien Mazières2, Jacques Margery3, Laurent 
Greillier4, Clarisse Audigier-Valette5, Denis Moro-Sibilot6, Olivier Molinier7, Romain Corre8, 
Isabelle Monnet9, Valérie Gounant10, Frédéric Rivière11, Henri Janicot12, Radj Gervais13, 
Chrystele Locher14, Bernard Milleron15, Quân Tran15, Marie Paule Lebitasy15, Christian 
Creveuil16, Jean-Jacques Parienti16, Franck Morin15, Gérard Zalcman16 1Pneumology, CHU 
Lille, Lille/France, 2Hôpital Larrey, Centre Hospitalier Universitaire de Toulouse, Toulouse/
France, 3Gustave Roussy, Villejuif/France, 4Hôpital Nord, Marseille/France, 5Chi Toulon, 
Toulon/France, 6Pôle Thorax Et Vaisseaux, Unité D’Oncologie Thoracique, Service de 
Pneumologie,, Grenoble/France, 7Ch Le Mans, Le Mans/France, 8CHU, Rennes/France, 9Chi 
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Percy, Clamart/France, 12CHU, Clermont-Ferrand/France, 13Centre François Baclesse, Caen/
France, 14Ch, Meaux/France, 15French Cooperative Thoracic Intergroup (Ifct), Paris/France, 
16CHU, Caen/France
Background: MPM median overall survival (OS) did not exceed 13 months with 
pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular 
endothelial growth factor is a potent mitogen for MPM cells. Methods: In this French 
multicenter randomized phase 3 trial, eligible patients had unresectable, histologically 
proved MPM, age < 76, no prior chemo, PS 0-2, no thrombosis, nor bleeding. 
Randomized patients (1:1) received pem 500 mg/m2, CDDP 75 mg/m2 at D1, with 
(arm B) or without bevacizumab (arm A), 15 mg/kg Q21D, for 6 cycles. Arm B non-
progressive patients received bevacizumab maintenance therapy until progression 
or toxicity. Primary endpoint was OS. 445 patients were to be randomized, and 385 
events observed, to show a significant OS improvement, with 80% statistical power, 
5% a-risk. Results: From Feb. 2008 to Jan. 2014, 448 patients were included in 73 
centers. Males: 75.4%, median age: 65.7 years (range 34.7-75.9), PS 0-1: 96.7%. The 
IDMC recommended a second interim analysis after 85% of events. On 01-Jan-2015, 
the duration since last news was < 30 days in 105 out of 106 still living patients. 
Overall survival was significantly longer in the experimental arm (median: 18.8 months, 
95%CI[15.9-22.6] vs. 16.1 months, 95%CI[14.0-17.9] for the reference arm, (adj.HR = 
0.76, 95%CI[0.61; 0.94], p = 0.012). With only 46/448 non-progressive patients at the 
date of analysis, median PFS was 9.6 months, 95%CI[8.5-10.6] in bevacizumab arm 
vs. 7.5 months, 95%CI[6.8-8.1] (adj.HR = 0.62, 95%CI[0.50-0.75], p < 0.0001). G3-4 
hematological toxicities did not significantly differ in the two arms (49.5% vs. 47.3%). 
Significantly more G3 proteinuria (0.0 vs. 3.1%), G3 hypertension (0.0 vs. 23%), G3-4 
arterial thrombotic events (0.0 vs. 2.7%) were observed in bevacizumab arm. QOL and 
exploratory biomarkers studies will be also presented at time of the meeting. Conclusion: 
Bevacizumab addition to pemetrexed/cis-platin provides a significantly longer survival in 
pts with MPM, with acceptable toxicity, making this triplet a new treatment paradigm. 
Keywords: IFCT, Mesothelioma, bevacizumab, phase III
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ORAL12.05 Impact of Time to Drug Approval on Potential Years of Life Lost: 
The Compelling Need for Improved Trial and Regulatory Efficiency David J. 
Stewart1, Andrew A. Stewart2, Paul Wheatley-Price1, Gerald Batist3, Hagop Kantarjian4, 
Joan Schiller5, Mark Clemons1, John-Peter Bradford6, Laurel Gibbons7, Razelle Kurzrock8 
1Medicine, University of Ottawa, Ottawa/ON/Canada, 2The Lethal Diseases Help Project, 
Ottawa/ON/Canada, 3Mcgill University, Montreal/QC/Canada, 4University of Texas MD 
Anderson Cancer Center, Houston/TX/United States of America, 5Hematology/Oncology, 
UT Southwestern, Dallas/United States of America, 6Bradford Bachinski Ltd and the Lethal 
Diseases Help Project, Ottawa/ON/Canada, 7The Ottawa Hospital and the Lethal Diseases 
Help Project, Ottawa/AB/Canada, 8University of California San Diego, San Diego/CA/United 
States of America
Background: Survival of incurable cancer patients is improving gradually. Several 
hundred new therapies are under development. However, internationally, regulatory 
complexity slows progress by increasing drug development costs (hence, fewer drugs 
can be assessed with available resources) and by producing numerous speed bumps 
that delay approval of useful drugs and that increase resources required to document 
that other agents are ineffective. Methods: We assessed cancer therapies undergoing 
phase III trials between 2001 and 2015. To be included, trials had to document 
statistically significant improvement in overall survival. We excluded adjuvant trials 
and trials in uncommon malignancies. To determine the number of life-years potentially 
lost per year required for drug approval, we multiplied the improvement in median 
survival in years by the estimated number of patients (North American and worldwide) 
dying annually from the relevant malignancy. Results: In the Table, we present the 
life-years lost per year required for approval for 21 therapies in 10 malignancies. 
When the combined impact of all tumor sites and drugs are considered together, there 
were 29 life-years lost in North America per hour of delay in therapy approval (1 for 
every 2 minutes of delay) and 260 life-years lost worldwide per hour of delay (1 for 
every 14 seconds of delay). These numbers do not take into account impact of drugs 
non-evaluable due to cross-over or missing survival data, drugs that were prematurely 
abandoned, drugs still undergoing investigation, or approaches for non-malignant lethal 
diseases. 
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The most frequent drug-related adverse event (AE) in the anamorelin arm in both 
ROMANA 1 and 2 was hyperglycemia (5.3% and 4.2%); there were few drug-related 
grade ≥3 AEs in the anamorelin arm versus the placebo arm (0.9% vs 1.2% and 2.7% 
vs 2.5%). Conclusion: Anamorelin significantly increased LBM and BW, and improved 
anorexia-cachexia symptoms and concerns, compared with placebo, in patients with 
advanced NSCLC and cachexia. Change from baseline in HGS was similar in both 
treatment arms. A significantly greater proportion of patients maintained/gained LBM 
in the anamorelin arm versus the placebo arm. When LBM was stable or increased, OS 
was significantly improved. Anamorelin treatment over 12 weeks was also well tolerated. 
Keywords: Cachexia, Anamorelin, ROMANA, Lean body mass
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strategies. We hypothesize young age at diagnosis (< 40 years) is a clinical characteristic 
associated with an increased chance for a targetable genomic alteration. Our ALCMI 
study prospectively characterizes the somatic and germline genomics of young lung 
cancer (GYLC). Our goals are to identify a genomically enriched subtype of lung 
cancer, facilitate delivery of targeted therapy and lay groundwork for further studies 
of heritable and environmental lung cancer risk factors. Methods: Accrual opened July 
2014. Patients are eligible if they were diagnosed with bronchogenic lung cancer less 
than age 40. A study website allows for virtual consenting so patients can participate 
remotely from anywhere in the world; and use social media to share our trial. We have 
an integrated data and bio repository that allows for seamless communication and 
completion of study activities like remote consenting and routing of blood and tumor 
specimens. We have defined 7 genomic alterations of interest based on the Lung 
Cancer Mutational Consortium (LCMC) (EGFR, KRAS, HER2, BRAF, ALK, ROS1, RET). 
We aim to demonstrate that the prevalence of targetable genomic alterations will be 
greater in our population compared to the LCMC and have powered our study to show 
an increase from 35% to 50%; and an improvement in use of targeted therapy from 
22% to 40%. On study subjects without a known genotype will undergo comprehensive 
genomic profiling with the FoundationOne test to ensure that all of these genes have 
been tested. Subjects with advanced adenocarcinoma who are wild type for all 7 genes 
will receive additional genomic profiling using the FoundationOne Heme test; with the 
goal of identifying novel oncogenic drivers. Additional investigational genomics will 
include blood for germline analysis and plasma genomics. All on study genomic analysis 
is at no cost to the participant. Results: Preliminary results of the first 33 subjects 
show: Average age at diagnosis: 33 years; Range 22-39; Histology: adenocarcinoma 
n=29, squamous cell n=4; Stage at diagnosis: stage 4 n=26 (79%) stages 1-3 n=7 
(21%). Of those with stage 4 adenocarcinoma (n=24); 18:24 (75%) have either an ALK 
re arrangement n=10 (42%), an EGFR activating mutation n=5 (21%) or a ROS1 fusion 
n=3 (13%). Conclusion: The trial is currently accruing (NCT02273336) https://www.
openmednet.org/site/alcmi-goyl. We have accrued patients from the USA, Europe and 
Australia. Thus far in our prospective series those diagnosed with primary NSCLC < 
age 40 tend to have stage 4 adenocarcinoma. Preliminary results exceed our statistical 
expectation with 75% of our metastatic adenocarcinoma patients having an actionable 
mutation. We plan on presenting data for the first time at WCLC-2015 on the first 50 
subjects. (Study, supported by grants from BJALCF, Beth Longwell Foundation, Peter 
Barker Foundation, Genentech, Schmidt Legacy Foundation, and Upstage Lung Cancer) 
Keywords: Young Lung Cancer, Virtual Consenting, enriched population, Genomics
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ORAL22.07 Oncogenic Profiling in Lung Adenocarcinoma Emerged in the Youth 
Kosuke Tanaka, Yuko Oya, Tatsuya Yoshida, Junichi Shimizu, Yoshitsugu Horio, Toyoaki 
Hida, Yasushi Yatabe Aichi Cancer Center, Nagoya/Japan
Background: EGFR, Kras mutations and EML4-ALK translocations were frequently 
positive in adenocarcinoma among lung cancer, and in fewer cases HER2, BRAF 
mutations or RET, ROS1 translocations were identified. Although adenocarcinomas 
emerged in the youth are estimatedly associated with some driver oncogenes 
including these mutations/translocations, the detail remains unknown. Methods: We 
retrospectively screened 55 consecutive patients who were diagnosed as stage I-IV 
adenocarcinoma at the age of 40 years or less in 2009-2014. We analyzed clinical and 
genetic characteristics among them. Results: Out of 55 patients, 21 (38%) were male, 
24 (44%) were never-smoker, and 38 (69%) were stage IV, with the median age of 36 
years (range; 26-40). Forty-five patients (82%) were identified some driver oncogene. 
26 (47%) had EML4-ALK translocation, 13 (24%) had EGFR mutation, and 2 (4%) had 
Kras mutation. We examined rare oncogenes in 10 out of 14 triple-negative patients, 
which revealed three patients had HER2 mutation and two had RET translocation. 
Conclusion: 82% of adenocarcinomas emerged in the youth were identified some 
targetable driver oncogenes. Not only EGFR mutation or EML4-ALK translocation, 
rare oncogene examination is necessary especially among these populations. 
Keywords: oncogene, Adenocarcinoma, youth
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ORAL24.03 Increasing Incidence of Non-Smoking Lung Cancer: Presentation 
of Patients with Early Disease to a Tertiary Institution in the UK Maria Elena 
Cufari1, Chiara Proli1, Manraj Phull1, Hilgardt Raubenheimer1, May Al Sahaf2, Nizar 
Asadi2, Periklis Perikleous2, Anna Allan2, Lynn Shedden1, Hemangi Chavan1, Zakiyah 
Niwaz3, Andre Kubler1, Andrew G. Nicholson4, Patrizia Viola5, Vladimir Anikin2, Emma 
Beddow2, Niall Mcgonigle2, Michael Dusmet1, Simon Jordan1, George Ladas1, Eric 
Lim1 1Department of Thoracic Surgery, Royal Brompton and Harefield NHS Trust, London/
United Kingdom, 2Thoracic Surgery, Royal Brompton and Harefield NHS Trust, London/
United Kingdom, 3Clinical Outcomes Analyst - Lung Division, Royal Brompton and Harefield 
NHS Trust, London/United Kingdom, 4Department of Histopathology, Royal Brompton and 
Harefield NHS Trust, London/United Kingdom, 5Histopathology, Royal Brompton Hospital, 
London/United Kingdom
Background: Lung cancer in never-smokers is recognised as a distinct entity. Many are 
expected to present late. As there are no established aetiological factors, identification 
of patients at risk is challenging. The aim of the study is to define the incidence and 
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ORAL22.01 Increasing Incidence of Never Smokers in Non Small Cell Lung 
Cancer (NSCLC) Patients Lorraine Pelosof1, Chul Ahn2, Leora Horn3, Alejandra 
Madrigales1, Joan Cox4, Judith N. Roberts5, John Minna1, Joan Schiller1 1Hematology/
Oncology, UT Southwestern, Dallas/TX/United States of America, 2Biostatistics, UT 
Southwestern, Dallas/TX/United States of America, 3Vanderbilt-Ingram Cancer Center, 
Nashville/TN/United States of America, 4Parkland Hospital, Dallas/United States of America, 
5Vanderbilt-Ingram Cancer Center, Nashville/United States of America
Background: It is estimated that 10-15% of lung cancer cases occur in never smokers. 
The cause of lung cancer in these patients includes many possible environmental factors 
but the precise cause in a given case is often uncertain. Additionally, there has been 
significant debate about whether the rate of lung cancer in these never smokers is 
increasing. Using our institutions’ cancer registry data, our objective was to determine if 
the proportion of never smokers with lung cancer is increasing. Methods: We conducted 
a retrospective study using lung cancer registry data from The University of Texas 
Southwestern Medical Center in Dallas, Parkland Hospital in Dallas, and Vanderbilt 
University in Nashville. These registries were queried between 1990 and 2013 for 
demographic information including gender, age at diagnosis, diagnosis [non small cell 
lung cancer (NSCLC) or small cell lung cancer (SCLC)], and self-reported smoking history. 
A total of 10,568 NSCLC cases and 1504 SCLC cases were analyzed. Logistic regression 
analysis was performed to assess the incidence of never smokers with lung cancer. 
Results: The percentage of never smokers increased among NSCLC pts between 1990 
and 2013 [Table 1]. Univariate logistic regression demonstrated an increasing proportion 
of never smokers among NSCLC cases (p < 0.0001 for year) and multivariate logistic 
regression also demonstrates this increase (p < 0.0001 for year) after controlling for 
age and gender. Never smokers with NSCLC were more likely to be female (65.3%, p < 
0.0001) than males. The increase in the percentage of NSCLC never smokers was seen 
at both university hospitals and the Dallas county hospital. In contrast, the percentage of 
never smokers among SCLC cases did not significantly increase during this time period.
Table 1: Percentage of never smokers
Conclusion: This multi-institution study demonstrates an increasing proportion of never 
smokers with NSCLC between 1990 and 2013 in a large, geographically and 
demographically diverse population. Because the biology and, thus, often the treatment 
options of lung cancer in never smokers differs from that of smokers, further investigation 
is warranted as to the etiology of the increasing incidence of never-smoker lung cancer. 
Keywords: never smoker, NSCLC
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ORAL22.05 The Genomics of Young Lung Cancer Study Barbara J. Gitlitz1, 
Deborah Morosini2, Alicia Sable-Hunt3, Bonnie J Addario3, Mark B. Jennings1, Silvia 
Novello4, Tiziana Vavala4, Stacy Mach5, Carol Jones6, Geoffrey R. Oxnard5 1University 
of Southern California Keck School of Medicine, Los Angeles/CA/United States of America, 
2Foundation Medicine, Boston/MA/United States of America, 3Addario Lung Cancer Medical 
Institute, San Carlos/CA/United States of America, 4University of Turin, Turin/Italy, 5Dana-
Farber Cancer, Boston/MA/United States of America, 6University of Southern California Keck 
School of Medicine, Los Angeles/United States of America
Background: Primary lung cancer is increasingly understood as a heterogeneous 
disease made up of genomically defined subtypes requiring distinct treatment 
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clinical features of never-smokers presenting sufficiently early for surgery to determine 
if it is possible to identify patients at risk. Methods: We retrospectively analysed data 
from a prospectively collected database of patients who underwent surgery at our 
institution. The incidence was defined as number of never-smokers versus current and 
ex-smokers by year. Clinical features at presentation were obtained and collated as 
frequency (percentage). Results: A total of 2170 patients underwent surgical resection 
for lung cancer from March 2008 to November 2014. The annual incidence of developing 
lung cancer in never-smokers increased from 13, 15, 18, 19, 20, 20 to 28 percent 
respectively, attributable to an absolute increase in number and not a change in the 
ratio of never smokers to current and ex-smokers. A total of 436 (20%) patients were 
never smokers. The mean age at presentation was 60 (16 SD) years and 295 (67%) 
were female. Good lung function was observed with mean predicted FEV1 of 90% (23 
SD) and FVC of 97% (25 SD). The majority histological types were adenocarcinoma 54% 
and carcinoid 27%. The main presenting features were non-specific consisting of cough 
in 142 (34%), chest infections in 75 (18%) and haemoptysis in 46 (11%). Recurrent chest 
infections were predominantly a symptom of central carcinoid tumours (30 versus 15 
percent; P=0.004). A total of 59 (14%) were detected on incidental chest film, 127 (30%) 
on incidental CT, 32 (7%) on incidental PET/CT and 4(1%) on incidental MRI. Conclusion: 
We observed more than double the annual incidence of never smokers presenting 
with non small cell lung cancer, in the last 7 years, increasing from 13 to 28 percent, 
and hypothesise that this is representative of the UK, as we are one of the highest 
surgical volume centres in our country. Patients present with non-specific symptoms 
and the majority were detected on incidental imaging. We conclude that imaging is 
likely to play a more important role and further efforts need to be expended on early 
detection of lung cancer in this increasing cohort without any observable risk factors. 
Keywords: never-smokers, non small cell lung cancer, early disease
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ORAL28.03 Genetic-Engineering Strategies to Enhance CAR T-Cell Therapy 
Efficacy against PD-L1 Expressing Lung Adenocarcinoma and Mesothelioma 
Leonid Cherkassky1, Aurore Morello1, Jonathan Villena-Vargas1, Marissa Mayor1, David 
R. Jones1, Michel Sadelain2, Prasad S. Adusumilli1 1Thoracic Surgery, Memorial Sloan-
Kettering Cancer Center, New York/United States of America, 2Center for Cell Engineering, 
Memorial Sloan Kettering Cancer Center, New York/United States of America
Background: Our laboratory has published (Sci Transl Med 2014) on the anti-tumor 
efficacy of mesothelin (MSLN)-targeted chimeric antigen receptor (CAR) transduced 
T cells. The purpose of this study is to investigate the efficacy of CAR T cells in a 
predominantly immunosuppressive environment in against lung adenocarcinoma (LAC) 
and malignant pleural mesothelioma (MPM) overexpressing PD-L1. We hypothesized that 
CAR T-cell efficacy can be inhibited by PD-L1 overexpression, which can be overcome 
by genetic engineering combining optimal costimulation and coinhibitory blockade to 
potentiate CAR T-cell efficacy. Methods: Human T cells were transduced with a CAR 
specific for MSLN and possessing CD3zeta domain alone (Mz) or CD3zeta domain and 
CD28 costimulation domain (M28z). To counteract PD1/PD-L1, M28z T cells were also 
costranduced with PD1 targeting shRNAs or with PD1 dominant negative receptor (PD1-
DNR), which contains the extracellular binding region of PD1 but lacks the intracellular 
signaling domain. T-cell efficacy (proliferation, cytokine secretion, cytotoxicity) was 
evaluated in vitro upon antigen repeated stimulation on PD-L1 expressing cell lines 
and in clinically-relevant MPM and LAC mouse models developed in the lab. A single 
low dose of CAR T cells were adoptively transferred intrapleurally or intravenously and 
anti-tumor efficacy was assessed by median survival and by tumor burden progression 
using bioluminescent imaging. Results: Compared to Mz T cells, M28z T cells bearing 
the CD28 costimulation domain exhibit an enhanced cytotoxicity, Th1 cytokine secretion 
and proliferation even in the presence of PD-L1 expressing cells. In vivo, M28z T cells 
exhibit higher persistence and prolong median survival compared to Mz (64 vs 29 days, 
p<0.05). However, when treated with a lower dose (E:T 1:12,000) of M28z T cells, treated 
mice died from tumor relapse; tumor harvest analysis demonstrated upregulation of 
PD1 and PD-L1 on T cells and tumor cells, respectively. Further analysis demonstrated 
that antigen-activated CAR T-cell secreted effector cytokines induced PD-L1 expression 
on cancer cells. We then confirmed in vitro that PD-L1/PD1 pathway promotes M28z 
T cells exhaustion by inhibiting cytotoxicity and cytokine secretion. M28z CAR T cells 
coexpressing shRNAs targeting PD1 or PD1-DNR lacking the intracellular signaling 
domain retained T cell effector function against PD-L1 expressing cancer cells. In vivo, 
mice treated with a low dose M28z PD1-DNR (E:T 1:12,000) had significantly enhanced 
tumor burden control and prolonged median survival (M28z vs M28z PD1-DNR, 56 vs 82 
days, p=0.001). Conclusion: Our results demonstrate the benefit of optimal signaling 
in CAR T cells by simultaneously providing costimulation and coinhibitory blockade 
to counteract PD-L1/PD1, a major mechanism of immunosuppression. This genetic-
engineering strategy is immediately translatable for clinical trials to enhance the efficacy 
of CAR T cell therapy, and is specific for MPM and LAC patient tumor microenvironment. 
Keywords: CAR T cells, PD-L1, Immunotherapy, immunosuppression
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PLEN04.01 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel 
or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab 
in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): SWOG 
S0819 Roy Herbst1, Mary Redman2, Edward S. Kim3, Thomas J. Semrad4, Lyudmila 
Bazhenova5, Gregory Masters6, Kurt Oettel7, Perry Guaglianone8, Christopher Reynolds9, 
Anand Karnad10, Susanne M. Arnold11, Marileila Varella-Garcia12, James Moon2, Philip C. 
Mack13, Charles D. Blanke14, Fred R. Hirsch12, David R. Gandara4 1Medical Oncology, Yale 
Cancer Center, New Haven, CT/United States of America, 2Swog Statistical Center, Portland/
OR/United States of America, 3Levine Cancer Institute, Carolinas Healthcare System, 
Charlotte/NC/United States of America, 4University of California at Davis, Sacramento/
CA/United States of America, 5Moores Cancer Center, University of California San Diego, 
La Jolla/United States of America, 6Helen F. Graham Cancer Center & Research Institute, 
Wilmington/DE/United States of America, 7Gundersen Lutheran CCOP/Gundersen Health 
System, Lacrosse/WI/United States of America, 8Heartland Cancer Research NCORP/Cancer 
Care Specialists of Central Illinois, Decatur/IL/United States of America, 9Michigan Cancer 
Research Consortium NCORP/St. Joseph Mercy Health System, Ann Arbor/MN/United States 
of America, 10University of Texas Health Science Center at San Antonio, Santo Antonio/TX/
United States of America, 11Medical Oncology, University of Kentucky, Lexington/KY/United 
States of America,12Medicine, University of Colorado School of Medicine, Aurora/United 
States of America, 13UC Davis Comprehensive Cancer Center, Sacramento/CA/United States 
of America, 14Swog Group Chair’s Office/Oregon Health & Science University, Portland/OR/
United States of America
Background: Cetuximab, a chimeric monoclonal antibody targeting the epidermal 
growth factor receptor (EGFR), moderately increases survival in patients with advanced 
NSCLC. Our prior work suggested that EGFR gene copy number measured by fluorescent 
in-suit hybridization (FISH) could identify those patients most likely to benefit. Methods: 
Patients eligible for this NCTN multicenter open-label, phase III trial had histologically 
or cytological confirmed Stage IV NSCLC that was newly diagnosed or recurrent after 
previous surgery or radiation. Patients with controlled brain metastases were allowed 
entry. All patients were required to have tumor tissue available for EGFR FISH testing. 
Randomization was stratified by appropriateness for bevacizumab treatment, smoking 
status and M-substage.  The co-primary objectives were progression-free survival 
(PFS) in EGFR-FISH positive (FISH+) patients and overall survival (OS) in the overall 
study population (OSP).  Secondary objectives were OS in FISH-positive patients and 
clinical outcomes (PFS and OS) comparison among bevacizumab-appropriate (BA) and 
inappropriate (BI) patients. Results: The final accrual was 1,333 total and 1,313 eligible 
patients (control arm: 657 total, 275/382 BA/BI; cetuximab-containing arm: 656 total, 
279/377 BA/BI). EGFR FISH status was determined on 976 patients, with 400 (41%) 
FISH+. Squamous carcinoma (SCCA) represented 24-25% of patients. PFS and OS were 
not significantly different in the OSP (HR (95%CI) =0.98 (0.87-1.09) and 0.94(0.84-1.06), 
respectively). There is some indication of benefit in PFS and OS (HR 0.91 (0.74-1.12) 
and 0.83 (0.67-1.04), respectively) in FISH+ patients, albeit not statistically significant. 
However, among FISH+ BI and SCCA patients, effect estimates for OS were 0.75 (0.57-
1.00) and 0.56 (0.37-0.84), respectively. Cetuximab was generally well tolerated with a 
spectrum of adverse events consistent with prior reports Conclusion: The addition of 
cetuximab had minimal effect in unselected advanced NSCLC patients.  In FISH+ patients 
there is a suggestion of benefit, predominantly in SCCA and BI.  These data support 
using a new marker for determining who should receive an EGFR antibody inhibitor with 
chemotherapy. Support: NIH/NCI/NCTN grants SWOG: CA180888, CA180819; ECOG/
ACRIN: CA180820; Alliance: CA180821; and in part by Bristol-Myers Squibb Co.
N PFS OS
Analysis Group OSP FISH+ OSP FISH+ OSP FISH+
All Patients
Cetuximab-Containing Arm, Median, 95% CI 656 199 4.6(4.2-5.2) 5.4(4.5-5.7) 10.9(9.6-12.0) 13.4(11.7-14.8)
Control Arm, Median, 95% CI 657 201 4.5(4.2-4.9) 4.8(3.9-5.5) 9.4(8.7-10.3) 9.8(8.7-12.1)
Hazard Ratio, 95% CI 0.98(0.87-1.09) 0.91(0.74-1.12) 0.94(0.84-1.06) 0.83(0.67-1.04)
2-sided p-value 0.68 0.37 0.34 0.10
BA
Cetuximab-Containing Arm, Median, 95% CI 279 86 5.6(5.3-6.1) 6.2(5.7-7.4) 12.7(10.9-13.4) 15.5(13.4-18.4)
Control Arm, Median, 95% CI 275 80 5.9(5.5-6.6) 6.7(5.7-8.0) 11.6(10.5-13.8) 13.2(11.2-19.1)
Hazard Ratio, 95% CI 1.05(0.88-1.25) 1.07(0.77-1.47) 1.04(0.86-1.25) 0.97(0.69-1.38)
2-sided p-value 0.57 0.70 0.70 0.88
BI
Cetuximab-Containing Arm, Median, 95% CI 377 113 4.1(3.6-4.4) 4.5(3.8-5.2) 9.2(8.2-10.9) 11.2(8.6-12.9)
Control Arm, Median, 95% CI 382 121 3.8(3.1-4.2) 3.7(2.8-4.6) 8.2(7.3-8.7) 8.7(5.9-9.7)
Hazard Ratio, 95% CI 0.93(0.80-1.07) 0.82(0.63-1.07) 0.88(0.76-1.03) 0.75(0.57-1.00)
2-sided p-value 0.31 0.14 0.12 0.05
SCCA
Cetuximab-Containing Arm, Median, 95% CI 160 55 4.2(3.7-4.6) 4.5(3.8-5.2) 9.6(8.2-11.5) 11.8(8.6-13.5)
Control Arm, Median, 95% CI 161 56 3.7(2.8-4.3) 2.8(2.6-4.1) 8.0(7.1-8.9) 6.4(4.2-8.7)
Hazard Ratio, 95% CI 0.88(0.70-1.11) 0.68(0.46-1.01) 0.85(0.67-1.08) 0.56(0.37-0.84)
2-sided p-value 0.29 0.06 0.18 0.006
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Background: EGFR mutant (M+) NSCLC is an archetypical oncogene-driven solid tumor, 
typified by high response rates when treated with a tyrosine kinase inhibitor (TKI), and 
median progression free survival of 10 months, commonly due to emergence of T790M. 
The genomic architecture and spectra of EGFR M+ tumours may provide insights to 
mechanisms of treatment failure and has not been well described to date. Methods: Paired 
tumor-normal exome/ transcriptome sequencing and SNP array was performed on 30 
tbiopsies from 25 patients with TKI resistance (TKI-R) as well as multiple regions (n=46) 
of 8 treatment naïve (TKI-N), never smoker East Asian EGFR M+ NSCLC (L858R, n=5; 
exon 19 del, n=2; exon 20 ins, n=1). Genomic alterations were validated with targeted 
re-sequencing at a mean depth of 2000x. Alterations were identified and annotated 
using established pipelines. Results: Exome sequencing of 46 sectors (4-11 sectors/
tumor) from 8 resected NSCLC (Stage IA, n=5; Stage IB, n=3), revealed a median of 
52.5 validated mutations (Range: 15-112) per tumor. Primary EGFR mutations (including 
exon 20 ins) were identified as truncal events in all cases, with the notable absence of 
T790M even at sequencing depths of 2000x. Private mutations comprised 10-33% of all 
mutations per tumor, and in some cases harbored potential drivers of subclonal diversity 
including p53, AKT1 and ATXN1. For the 30 TKI-R tumors (T790M+, n=16; T790M-, 
n=14), exome sequencing revealed a higher mutation burden (median 80 vs 49 in 
TKI-N), while SNP array and expression data confirmed ERBB2 and MET as common co-
existing resistance mechanisms. We next inferred the relevance of alterations and their 
hierarchical order (trunk, T; branch, B; private, P). In a TKI-N tumor where 11 sectors were 
subject to exome-sequencing, 39 of 112 mutations were truncal events – with MAP3K19 
and PTEN splice site mutations co-existing with EGFR L858R mutation. Strikingly, when 
comparing the transcriptomic profiles of TKI-N and TKI-R tumors, all 8 evaluated sectors 
in this tumor clustered together with the TKI-R signature, suggesting that truncal co-
mutations can contribute to primary TKI resistance. Finally, we attempted to curate novel 
genes in the 46 TKI-N sectors that may be implicated in TKI resistance by identifying 
genes in common with those altered in TKI-R samples with allele frequency > 0.25. We 
shortlisted approximately 150 recurrent genes or putative drivers – 85% of which were 
either trunk or branch mutations including TP53 (T,P), PTEN (B), LRP1B (B), GPRIN3 (B), 
MAP3K19 (T), ARID3A (P) and MED12 (P). Conclusion: Multi-region sequencing of 8 never 
smoker EGFR M+ NSCLC revealed a low mutation burden, with a significant proportion of 
alterations occurring as trunk or branch events. The different activating EGFR mutations 
were ubiquitous truncal events and T790M was not found in ultra-deep sequencing 
across 46 sectors. Mutation hierarchy provides a basis for patterns of TKI treatment 
failure: with co-occurring truncal events (e.g. MAP3K19, PTEN) potentially contributing 
to primary resistance, and the low incidence of private subclonal drivers consistent with 
the relatively high prevalence of T790M mutation in the setting of secondary resistance. 
Keywords: Tumor heterogeneity, EGFR mutation, NSCLC, TKI resistance
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Background: The National Lung Screening Trial (NLST) has achieved a 7% reduction 
in mortality from any cause with low-dose computed tomography (LDCT) screening, 
as compared with the chest radiography arm. Other randomized trials are under way, 
comparing LDCT screening with no intervention in heavy smokers populations. None 
of these studies is designed to investigate the impact of smoking habits on screening 
outcome. In the present study, we have tested the effect of stopping smoking on the 
overall mortality of volunteers undergoing LDCT screening. Methods: Between 2000 
and 2010, 3381 heavy smokers aged more than 50 years were enrolled in two LDCT 
screening programmes. Sixty-nine percent were males with median age of 58 years and 
median smoking exposure of 40 pack-years. Based on the last follow-up information, 
subjects were divided in two groups: current smokers throughout the screening period, 
and former smokers. The latter group included ex-smokers at the time of baseline 
screening (early quitters), and those who stopped smoking during the screening period 
(late quitters).The effect of smoking on mortality was adjusted according to the following 
covariates: gender, age, body-mass index (BMI), lung function (FEV1 %) and pack years at 
baseline. Results: With a median follow-up time of 9.7 years, and a total of 32,857 person/
years (P/Y) follow-up, a total of 151 deaths were observed in the group of 1797 current 
smokers (17,846 P/Y) and 109 in 1584 former smokers (15,011 P/Y). As compared to 
current smokers, the Relative Risk (RR) of death of former smokers was 0.77 (95% CI, 
0.60 to 0.99, p = 0.0416), corresponding to a 23% reduction of total mortality. Excluding 
239 subjects who had stopped smoking from less than 2 years from the end-point of 
follow-up, RR was 0.64 (95% CI, 0.48 to 0.84, p = 0.0016), with a 36% mortality reduction. 
A similar risk reduction was observed in the subset of 476 late quitters (27 deaths, 
4,777 P/Y), with a RR of 0.60 (95% CI, 0.40 to 0.91, p = 0.0158). Conclusion: Stopping 
smoking is associated with a significant reduction of the overall mortality of heavy 
smokers enrolled in LDCT screening programs. The benefit of stopping smoking appears 
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States of America, 18Vanderbilt University Medical Center, Nashville/TN/United States of 
America, 19Winship Cancer Institute, Emory University, Atlanta/GA/United States of America, 
20Hematology/Oncology, UT Southwestern, Dallas/United States of America
Background: Adjuvant chemotherapy for resected early stage NSCLC provides 
modest survival benefit. Bevacizumab, a monoclonal antibody directed against 
vascular endothelial growth factor, improves outcomes when added to platinum-based 
chemotherapy in advanced stage non-squamous NSCLC. We conducted a phase 3 
study to evaluate the addition of bevacizumab to adjuvant chemotherapy in early stage 
resected NSCLC. The primary endpoint was overall survival and secondary endpoints 
included disease-free survival and toxicity assessment. Methods: Patients with resected 
stage IB (>4 centimeters) to IIIA (AJCC 6th edition) NSCLC were enrolled within 6-12 
weeks of surgery and stratified by chemotherapy regimen, stage, histology and sex. 
All patients were to receive adjuvant chemotherapy consisting of a planned 4 cycles of 
every 3 week cisplatin at 75 mg/m2 with either vinorelbine, docetaxel, gemcitabine or 
pemetrexed. Patients were randomized 1:1 to arm A (chemotherapy alone) or arm B, 
adding bevacizumab at 15 mg/kg every 3 weeks starting with cycle 1 of chemotherapy 
and continuing for 1 year. Post-operative radiation therapy was not allowed. The study 
had 85% power to detect a 21% reduction in the overall survival (OS) hazard rate with a 
one-sided 0.025-level test. Results: From July 2007 to September 2013, 1501 patients 
were enrolled. Patients were 49.8% male, predominantly white (87.9%) with a median 
age of 61 years. Patients enrolled had tumors that were 26.2% stage IB, 43.8% stage II 
and 30.0% stage IIIA and 28.2% of patients had squamous cell histology. Chemotherapy 
options were utilized with the following distribution: vinorelbine 25.0%, docetaxel 
22.9%, gemcitabine 18.9% and pemetrexed 33.2%. At a planned interim analysis, 
with 412 of 676 overall survival events needed for full information (60.9%), though the 
pre-planned futility boundary was not crossed, the Data Safety Monitoring Committee 
recommended releasing the trial results based on the conditional power of the logrank 
test. At the time of interim analysis, with a median follow-up time of 41 months, the 
OS hazard ratio comparing the bevacizumab containing arm (Arm B) to chemotherapy 
alone (Arm A) was 0.99 (95% CI: 0.81-1.21, p=0.93). The DFS hazard ratio was 0.98 
(95% CI: 0.84-1.14, p=0.75). Completion of treatment per protocol was 80% on Arm A 
and 36% on Arm B. Statistically significantly increased grade 3-5 toxicities of note (all 
attributions) included: overall worst grade (67% versus 84%); hypertension (8% versus 
30%), and neutropenia (33% versus 38%) on Arms A and B, respectively. There was no 
significant difference in grade 5 adverse events per arm with 16 (2%) on arm A and 19 
(3%) on arm B. Conclusion: The addition of bevacizumab to adjuvant chemotherapy 
failed to improve survival for patients with surgically resected early stage NSCLC. 
Keywords: adjuvant chemotherapy, bevacizumab, early stage NSCLC
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targeted NGS demonstrating similar findings, but with high-grade AXL amplification (13 
copies). IHC analyses also indicated MET expression (3+) and PD-L1 negativity. He was 
enrolled in the Phase 1b expansion portion of the Study 265-101 and was treated with 
MGCD265 at 1050 mg BID starting April 23, 2015. Results: The patient experienced 
rapid clinical improvement after treatment with MGCD265. He was oxygen-dependent 
prior to starting the trial and is currently able to bike 7 miles per day. Tumor imaging 
obtained after 2 cycles of treatment on June 2, 2015 showed a partial response (PR) with 
a decrease in index lesions of 42.3%, compared to baseline tumor imaging on April 22, 
2015. The PR was confirmed after 4 cycles on treatment (July 14, 2015) with a decrease 
from baseline tumor imaging of 48.8% in index lesions. Other than Grade 1 diarrhea and 
AST/ALT elevation, he has experienced no other toxicities on study. Conclusion: To 
our knowledge, this is the first documentation of objective response of a NSCLC patient 
with AXL amplification treated with a small molecule inhibitor of AXL suggesting that AXL 
alterations may act as oncogenic drivers. Further study of MGCD265 in tumors with AXL 
genetic alterations is warranted. 
to be 3 to 5-fold greater than the one achieved by earlier detection in the NLST trial. 
Keywords: overall mortality, stopping smoking, LDCT screening, heavy smokers
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Background: SQUIRE, a randomized phase III study, demonstrated that the addition of 
necitumumab (N) (a second-generation, recombinant, human immunoglobulin G1 EGFR 
antibody) to gemcitabine-cisplatin (GC) improved overall survival (OS) in patients with 
stage IV squamous non-small cell lung cancer (NSCLC). Analyses of the relationship 
between efficacy and epidermal growth factor receptor (EGFR) protein expression 
using the immunohistochemistry (IHC) H-score=200 cut-point were previously reported 
(Thatcher et al. Lancet Onc, 2015; doi: 10.1016/S1470-2045(15)00021-2). Here we 
report additional exploratory analyses of the relationship with EGFR protein, as well 
as analyses of EGFR gene copy number. Methods: SQUIRE included mandatory tissue 
collection from archived tumor. EGFR protein expression was assessed by IHC in a 
central lab, using the Dako EGFR PharmDx kit. Analyses of the relationships between 
efficacy outcomes with EGFR across the range of protein levels were performed, using 
methodologies including subpopulation treatment effect pattern plot (STEPP) with a 
sliding window target size of 200 patients. An exploratory assessment of EGFR gene copy 
number gain was performed in tissue sections using fluorescence in situ hybridization 
(FISH) (J Clin Pathol; 2009;62(11):970-7). Efficacy outcomes were estimated using the 
Kaplan-Meier method and hazard ratios estimated using an un-stratified Cox model. . 
Results: A total of 982 patients (89.8% of the ITT) had evaluable IHC assay results. The 
large majority of these patients (95.2%) had tumor samples expressing EGFR protein; 
only 4.8% had tumors without detectable EGFR protein (H-score=0). The STEPP analyses 
showed no consistent trend or obvious cut-point for the relationship between either OS 
or PFS with EGFR protein across the range of IHC values when comparing treatment 
arms. Archived tumor tissue with evaluable results for exploratory EGFR FISH analysis 
was available for 51.0% of patients (557 of 1093 ITT patients). Of these patients, 208 
patients (37.3%) had increased EGFR gene copy number (FISH positive). A trend for 
greater necitumumab benefit was observed in EGFR FISH positive patients. Treatment 
HR (95% CI) for FISH positive and negative patients were 0.70 (0.52, 0.96) and 1.02 
(0.80, 1.29) for OS, and 0.71 (0.52, 0.97) and 1.04 (0.82, 1.33) for PFS. However, the 
interaction of EGFR gene copy number gain with treatment was not statistically significant 
for either OS or PFS (p=0.066 and 0.057, respectively). Conclusion: The analysis of 
EGFR protein expression did not identify consistent trends related to efficacy outcomes 
across the range of IHC values. EGFR gene copy number gain showed a trend for a 
more favorable HR, but did not appear to be strongly predictive. However, both markers 
showed some evidence of potential trends that will be investigated further in future trials. 
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Background: MGCD265 is a spectrum-selective small molecule inhibitor of the AXL and 
MET receptor tyrosine kinases (RTKs). AXL and MET may be activated in NSCLC by gene 
mutation, amplification or rearrangement, resulting in oncogene addiction. Additionally, 
these RTKs are implicated in the progression of NSCLC and in acquired resistance to 
EGFR inhibitors. Although AXL genomic abnormalities have been reported in NSCLC, 
therapeutic targeting of such alterations with AXL inhibitors has not been clinically 
validated. Here we report the first documented objective response in a patient with AXL-
amplified NSCLC with a small molecule AXL inhibitor. Methods: A 56 year- old male, 
never-smoker, was diagnosed with metastatic adenocarcinoma of the lung, with bilateral 
mediastinal lymphadenopathy and pleural carcinomatosis. Targeted next-generation 
sequencing (NGS) demonstrated AXL low amplification (estimated 5 copies), CDKN2A/B 
loss, CCNE1 amplification, AKT2 amplification and MTOR mutation (p.R132C). The tumor 
was wild-type for EGFR, ALK, ROS1, RAS and MET. He was treated with carboplatin/ 
pemetrexed and bevacizumab, followed by docetaxel, with a best response of stable 
disease. Based on CCNE1 amplification, he was also enrolled in a clinical trial combining 
an ATR inhibitor with cisplatin. His course was complicated by pneumonia and continued 
disease progression. A second biopsy was procured after initial chemotherapy, with 
